Capital expenditure · 2017–2025
Bridgebio Pharma capital expenditure
$1.1M+17.6% · FY2025
Bridgebio Pharma (BBIO) reported $1.1M in capital expenditure for fiscal 2025, +17.6% year on year.
| Fiscal year | Capital expenditure | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $1.1M | +17.6% | Open → |
| FY20242024-12-31 | $933,000 | −28.6% | Open → |
| FY20232023-12-31 | $1.3M | −72.9% | Open → |
| FY20222022-12-31 | $4.8M | −63.6% | Open → |
| FY20212021-12-31 | $13.2M | +76.2% | Open → |
| FY20202020-12-31 | $7.5M | +185.0% | Open → |
| FY20192019-12-31 | $2.6M | +21.1% | Open → |
| FY20182018-12-31 | $2.2M | +369.4% | Open → |
| FY20172017-12-31 | $464,000 | — | Open → |
Capital expenditure — Capital expenditure is the cash the company spent during the year on property, plant and equipment — factories, stores, servers, vehicles. It appears in the investing section of the cash-flow statement as an outflow and is shown here as a positive amount. Operating cash flow minus this figure is free cash flow.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2017–2025 compound annual growth +11.4%
Capital expenditure at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Bridgebio Pharma capital expenditure |url=https://companiesranked.com/en/company/bridgebio-pharma/capital-expenditure |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Bridgebio Pharma capital expenditure. CompaniesRanked. https://companiesranked.com/en/company/bridgebio-pharma/capital-expenditureBibTeX
@misc{companiesranked-en-company-bridgebio-pharma-capital-expenditure-2026,
author = {{CompaniesRanked}},
title = {{Bridgebio Pharma capital expenditure}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/bridgebio-pharma/capital-expenditure}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001743881-26-000009 · February 24, 2026
{{cite web |title=Bridgebio Pharma capital expenditure — 10-K (0001743881-26-000009) |url=https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.